SYF628024db65dd458e99c88bbcaceea2ccRegistry ID: 2022-500906-17-01|RecruitingPhase 2
INVITED trial
INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED trial)
Aarhus University Hospital
Loading search results
INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED trial)
interventional
N/A
1 country
10
To determine whether or not influenza vaccination will preserve β cell function in early type 1 diabetes mellitus.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 24, 2022
Actual (reported)Change in fasting residual β cell (C-peptide) function, baseline to 12 months.
Change in fasting C-peptide levels, baseline to 6 months.
Change in HbA1c, baseline to 12 months.
Change in insulin requirements, baseline to 12 months (measured as total insulin dose per kg body weight per day as a mean for the last 14 days).
Time-In-Range (3.9-10.0 mmol/L) of continuous glucose monitoring over 14 days at 12 months.
Percent coefficient of variation of glucose (%CV) over 14 days at 12 months.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Nykoebing F Sygehus
Nykobing F, 4800, Denmark
Region Midtjylland
Viborg, 8800, Denmark
Aalborg University Hospital
Aalborg, 9000, Denmark
Mads Fuglsang Kjolby
First Submitted
June 24, 2022
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
Contact the study team to confirm eligibility.
Region Midtjylland
Herning, 7400, Denmark
Steno Diabetes Center Copenhagen
Herlev, 2730, Denmark
Aarhus University
Aarhus N, 8200, Denmark
Regionshospitalet Randers
Randers Nø, 8930, Denmark
Holbaek Sygehus
Holbæk, 4300, Denmark
Slagelse Hospital
Slagelse, 4200, Denmark
Region Sjaelland
Roskilde, 4000, Denmark